Biosimilars Market Research Reports & Industry Analysis

Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of $140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incide...

Europe biosimilars market was valued at $5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic di...

Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases d...

North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising inciden...

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. ?Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026? Report h...

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. ?US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026? Report Highligh...

Asia Pacific BOPP and BOPET films demand stood at 2.09 Million Tonnes in 2020 and is forecast to reach 3.476 Million Tonnes by 2030, growing at a healthy CAGR of 5.04% until 2030. The rise in e-commer...

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. 'US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 20...

Global glycobiology market was valued at USD 938.76 Million in 2019 and is expected to grow at a double digit CAGR of 13.83% during the forecast period. The global glycobiology market is driven by the...

Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and...

Biosimilars have a very complex molecular structure and they have similar characteristics as compared to their reference medicine. Biosimilars are mainly used to derive known effective medicinal produ...

“Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinctAfter a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Ch...

Europe biosimilar insulin glargine and lispro market is projected to reach $ 1.9 billion by 2024 owing to rising levels of obesity, growing expenditure on healthcare and increasing adoption of sedenta...

... Phase: 28 Biosimilars Marketed Biosimilars Clinical Insight by Company & Indication: 9 Biosimilars Biosimilars Market Opportunity: US$ 5 Billion FDA Rules & Regulations For Biosimilars Development & Market Approved & Marketed Biosimilars: Clinical Insight, Price & Dosage 'US Biosimilars Market, Dosage, Price ...

... – 2018 to 2025 Target Audience of the Global G-CSF Biosimilars Market in Market Study: Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value ...

This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, ... forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary ...

... the expansion of the biosimilars market across ASEAN and China. The ASEAN and China biosimilars market is segmented into molecule ... market is analyzed across China and ASEAN region. Key Benefits ASEAN and China Biosimilars Market: The study provides an in-depth analysis of the ASEAN and China biosimilars market ...

... 2018). You won't find entrenched perceptions, old data and out-of-date opinions. Instead, Biosimilars: US Payer Perspectives ... Example insight included in Biosimilars: US Payer Perspectives Payers have devised strategies to encourage the adoption of biosimilars. Currently, payers require prior authorisations, ...

... the growth this market to a large extent. Market Analysis: The “Global Biosimilars Market” is estimated to witness a CAGR of 57.03% during the forecast period 2018–2024. The market is analyzed based on three ...

... relation to Humira biosimilars Future challenges and opportunities in the European biosimilars market Example insight included in Biosimilars: EU Payer Perspectives 'Aligned with ... been hugely successful.' Example quote included in Biosimilars: EU Payer Perspectives 'There have been huge cost savings over ...

... , Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 Global Biosimilars Market Report Description: Global biosimilars market report gives a comprehensive outlook on biosimilars products across the ...

... and many other questions can be found in Charting the Global Biosimilars Pipeline. This comprehensive report provides the most detailed evaluation ... biosimilar companies Biosimilar pipeline by product BIOSIMILAR PIPELINE BY PRODUCT Each biosimilar monograph utilises well-structured tables and charts to provide ...

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin ...

... believe companies need to choose 'a road less travelled'? Commercialisation of Biosimilars: Team Tactics & Strategies Across the Product Lifecycle reveals what ... to optimal strategy development and implementation for biosimilars Key insights As the biosimilar market matures, commercial strategies will evolve to ...

... with systemic agents. Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class ...

... ~4000) and early entry of the player are critical factors to decide biosimilar penetration and market share dynamics of Japan Biosimilar Market. While ... in next few years for Japan biosimilar players. In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, ...

... prices addressed. Real World Data (RWD) and Real World Evidence (RWE) play a key role in building stakeholder confidence and establishing market presence. In Biosimilars Real World Evidence: Proving the point ...

... be involved in decisions about biosimilars? Will biosimilar oncology mAbs see widespread uptake? What should developers target next? For biosimilars to thrive, payers must ... on clinical and patient biosimilar experience Content Highlights Biosimilars in Europe: current status, key developments Key insights Overview The European biosimilars market continues ...

... Netscribes’ latest market research report titled Biosimilars Market in India 2017, describes the current and forecasted dynamics of the biosimilars market in India. The increasing ... has resulted in the growth of this industry in India. Biosimilars are typically marketed at prices that are 25% to 40% below the ...

... emerging-market industry Pipeline of biosimilar monoclonal antibodies in emerging markets Pipeline of non-monoclonal antibody biosimilars in emerging markets In market access, biosimilar players face different challenges to originators Funding & pricing attributes of leading emerging markets ...

The Global Biosimilar Drug Market Analysis & Forecast Report 2017-2022 is a professional and in-depth study on the current state of the Biosimilar Drug Market. The report analysis the global market of Biosimilar Drug by main manufactures and geographic regions. The report includes Biosimilar Drug definitions, classifications, applications and ...

... Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market ...

... “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share ... current and future trends. Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling ...

... 1. Global Biosimilars Market and Forecast - By Product Type 2. Global Biosimilars Market and Forecast - By Applications 3. Global Biosimilars Market and Forecast - By Country Wise 4. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis 5. Country with Biosimilar Guideline ...

... Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilar version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials ...

... Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials ...

... Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials ...

... on the location. “Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ...

... location. “Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are ...

... recent approval of three biosimilars in the US market is providing an impetus to more biopharmaceutical companies to enter this field. As per RNCOS report “Global Biosimilar Market Outlook 2022”, the global biosimilars market is anticipated to witness a high double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market ...

... . However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost. As per RNCOS report “EPO Biosimilars - The ... segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available ...

... biosimilars is growing. Aruvian Research analyzes the global biosimilars industry in its research report Analyzing the Global Biosimilars Industry 2016. In this research report, we analyze what biosimilars ... -wise analysis of the biosimilar industry. Biosimilar markets are analyzed in Australia, BRIC nations ...

... Understand the Forces Shaping the Biosimilars Market Commercialisation: Differentiation may be the key success factor for biosimilars. Discover the strategies manufacturers ... biosimilars in Europe shaped attitudes toward switching both treatment-naïve and established patients to biosimilars? Getting crowded: How will the market handle multiple biosimilars ...

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ...

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...